Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“JCOG1008 5-year update is here.
The long-standing debate over weekly vs 3-weekly cisplatin in postoperative head and neck cancer may finally have an answer.
JCOG1008
Postoperative high-risk LA-SCCHN
Weekly cisplatin (40 mg/m²) plus RT vs 3-weekly cisplatin (100 mg/m²) + RT
Key results (median follow-up: 5.6 years):
5-year OS
- 71.2% vs 58.7%
- HR 0.76 (95% CI 0.52-1.12)
- Noninferiority confirmed
5-year RFS
- 64.3% vs 53.0%
- HR 0.81
5-year Local RFS
- 68.8% vs 57.2%
- HR 0.79
No clinically meaningful increase in late toxicity.
Acute toxicity remained more favorable with weekly cisplatin.
Take-home:
Weekly cisplatin is no longer just the ‘more convenient’ option.
It now has mature 5-year randomized data supporting it as a standard postoperative CRT regimen for high-risk LA-SCCHN.
Will this change your practice?”
Title: Long-Term Follow-Up of JCOG1008, a Randomized Phase II/III Trial of Chemoradiotherapy Comparing 3-Weekly Cisplatin With Weekly Cisplatin in Postoperative Head and Neck Cancer
Authors: Makoto Tahara, Naomi Kiyota, Takeshi Kodaira, Hiroshi Nishino, Yukinori Asada, Hiroki Mitani, Yuji Hirayama, Yusuke Onozawa, Naoki Nishio, Nobuhiro Hanai, Akira Ohkoshi, Hiroki Hara, Nobuya Monden, Masato Nagaoka, Shujiro Minami, Kaoru Tanaka, Takashi Fujii, Seiichi Yoshimoto, Tsutomu Ueda, Yo Kishimoto, Akihiro Homma, Nobuhiko Oridate, Kenji Okami, Hirokazu Uemura, Katsunori Katagiri, Tomoko Yamazaki, Takahiro Asakage, Yuki Saito, Shigeyuki Murono, Junki Mizusawa, Kenichi Nakamura, Ryuichi Hayashi
Read the Full Article on Journal of Clinical Oncology
More posts featuring Rishabh Jain.
